Diabetes Care, Vol 21, Issue 5 841-848, Copyright © 1998 by American Diabetes Association

ARTICLES

Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM

MA Hofmann, B Kohl, MS Zumbach, V Borcea, A Bierhaus, M Henkels, J Amiral, AM Schmidt, W Fiehn, R Ziegler, P Wahl and PP Nawroth
Department of Medicine, University of Heidelberg, Germany.

OBJECTIVE: Considering that elevated blood levels of homocyst(e)ine represent a known independent risk factor for macrovascular disease, we assessed the link between hyperhomocyst(e)inemia and diabetic microvascular complications. RESEARCH DESIGN AND METHODS: Homocyst(e)ine and thrombomodulin plasma levels, a marker of endothelial cell damage, were measured before and 3 h after oral methionine loading in 75 patients with stable, well-controlled IDDM and 40 healthy control subjects matched for sex and age. Exclusion criteria were hyperlipidemia, hypertension, smoking, or positive family history for cardiovascular disease. RESULTS: IDDM patients had higher pre- and postload homocyst(e)ine plasma levels than did healthy control subjects (12.0 vs. 7.7 mumol/l and 27.6 vs. 16.0 mumol/l; P < 0.001). Of 75 IDDM patients, 26 had homocyst(e)ine plasma levels above the normal range (defined as mean +2 SD of values obtained in the control group). The IDDM patients with hyperhomocyst(e)inemia had higher thrombomodulin plasma levels (62.2 vs. 38.2 ng/ml; P < 0.001), higher albumin excretion rates (485 vs. 115 mg/l; P < 0.005), and a higher prevalence of late diabetic complications (nephropathy, 76 vs. 33%; retinopathy, 69 vs. 51%; neuropathy, 57 vs. 41%; macroangiopathy, 57 vs. 33%) compared with IDDM patients with normal plasma homocyst(e)ine. In vitro experiments with human umbilical vein cells show an increased release of thrombomodulin into the culture supernatant only when endothelial cells were pretreated with advanced glycation end product (AGE)-albumin before L-homocystine was added. A synergistic action of homocyst(e)ine and AGEs might contribute to vascular complications of patients with diabetes. CONCLUSIONS: Hyperhomocyst(e)inemia is common in nephropathic diabetic patients and may contribute to the enhanced morbidity and mortality from cardiovascular diseases characteristically observed in IDDM patients with diabetic nephropathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. S. Brown and E. S. Susser Prenatal Nutritional Deficiency and Risk of Adult Schizophrenia Schizophr Bull, November 1, 2008; 34(6): 1054 - 1063. [Abstract] [Full Text] [PDF]

				A. Akalin, O. Alatas, and O. Colak Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52. [Abstract] [Full Text] [PDF]

				A. S. Brown, T. Bottiglieri, C. A. Schaefer, C. P. Quesenberry Jr, L. Liu, M. Bresnahan, and E. S. Susser Elevated Prenatal Homocysteine Levels as a Risk Factor for Schizophrenia Arch Gen Psychiatry, January 1, 2007; 64(1): 31 - 39. [Abstract] [Full Text] [PDF]

				E. C. Dinleyici, B. Kirel, O. Alatas, H. Muslumanoglu, Z. Kilic, and N. Dogruel Plasma Total Homocysteine Levels in Children with Type 1 Diabetes: Relationship with Vitamin Status, Methylene Tetrahydrofolate Reductase Genotype, Disease Parameters and Coronary Risk Factors J Trop Pediatr, August 1, 2006; 52(4): 260 - 266. [Abstract] [Full Text] [PDF]

				K. E. MacKenzie, E. J. Wiltshire, R. Gent, C. Hirte, L. Piotto, and J. J. Couper Folate and Vitamin B6 Rapidly Normalize Endothelial Dysfunction In Children With Type 1 Diabetes Mellitus Pediatrics, July 1, 2006; 118(1): 242 - 253. [Abstract] [Full Text] [PDF]

				J. Chen and M. S. Goligorsky Premature senescence of endothelial cells: Methusaleh's dilemma Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1729 - H1739. [Abstract] [Full Text] [PDF]

				S. Ratnam, E. P. Wijekoon, B. Hall, T. A. Garrow, M. E. Brosnan, and J. T. Brosnan Effects of diabetes and insulin on betaine-homocysteine S-methyltransferase expression in rat liver Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E933 - E939. [Abstract] [Full Text] [PDF]

				J. Chen, X. Huang, D. Halicka, S. Brodsky, A. Avram, J. Eskander, N. A. Bloomgarden, Z. Darzynkiewicz, and M. S. Goligorsky Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53 Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1575 - H1586. [Abstract] [Full Text] [PDF]

				P. M. Martin, P. Roon, T. K. Van Ells, V. Ganapathy, and S. B. Smith Death of Retinal Neurons in Streptozotocin-Induced Diabetic Mice Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3330 - 3336. [Abstract] [Full Text] [PDF]

				F. Wotherspoon, D. W Laight, K. M Shaw, and M. H Cummings Review: Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 334 - 340. [Abstract] [PDF]

				M. Maeda, I. Yamamoto, M. Fukuda, M. Nishida, J. Fujitsu, S. Nonen, T. Igarashi, T. Motomura, M. Inaba, Y. Fujio, et al. MTHFR Gene Polymorphism as a Risk Factor for Diabetic Retinopathy in Type 2 Diabetic Patients Without Serum Creatinine Elevation Diabetes Care, February 1, 2003; 26(2): 547 - 548. [Full Text] [PDF]

				D. Browne, D. Meeking, K. Shaw, and M. Cummings Review: Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes -- pathogenesis and identification The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 27 - 34. [Abstract] [PDF]

				B. Ozmen, D. Ozmen, N. Turgan, S. Habif, I. Mutaf, and O. Bayindir Association Between Homocysteinemia and Renal Function in Patients with Type 2 Diabetes Mellitus Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 279 - 286. [Abstract] [Full Text] [PDF]

				E. J. Wiltshire, R. Gent, C. Hirte, A. Pena, D. W. Thomas, and J. J. Couper Endothelial Dysfunction Relates to Folate Status in Children and Adolescents With Type 1 Diabetes Diabetes, July 1, 2002; 51(7): 2282 - 2286. [Abstract] [Full Text] [PDF]

				B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]

				M. Emoto, H. Kanda, T. Shoji, T. Kawagishi, M. Komatsu, K. Mori, H. Tahara, E. Ishimura, M. Inaba, Y. Okuno, et al. Impact of Insulin Resistance and Nephropathy on Homocysteine in Type 2 Diabetes Diabetes Care, March 1, 2001; 24(3): 533 - 538. [Abstract] [Full Text]

				E. K. Hoogeveen, P. J. Kostense, P. E. D. Eysink, B. C. P. Polak, P. J. Beks, C. Jakobs, J. M. Dekker, G. Nijpels, R. J. Heine, L. M. Bouter, et al. Hyperhomocysteinemia Is Associated With the Presence of Retinopathy in Type 2 Diabetes Mellitus: The Hoorn Study Arch Intern Med, October 23, 2000; 160(19): 2984 - 2990. [Abstract] [Full Text] [PDF]

				A. Gottsater, I. Anwaar, K.-F. Eriksson, I. Mattiasson, F. Lindgarde, and A. Gottsater Homocysteine Is Related to Neopterin and Endothelin-1 in Plasma of Subjects with Disturbed Glucose Metabolism and Reference Subjects Angiology, June 1, 2000; 51(6): 489 - 497. [Abstract] [PDF]

				V. Fonseca, S. C. Guba, and L. M. Fink Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis Endocr. Rev., October 1, 1999; 20(5): 738 - 759. [Abstract] [Full Text]